1-Ethyl-3-methylimidazolium diethylphosphate28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean2.11µMPoint of departure: one standard deviation difference in viable cell count from control mean. 1-Ethyl-3-methylimidazolium diethylphosphate28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean0.200507006601622µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 1-Ethyl-3-methylimidazolium diethylphosphate28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean1.47408157603184µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. 1-Ethyl-3-methylimidazolium diethylphosphate28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean1.5579581982601103µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. 2-Ethylhexyl diphenyl phosphate28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean1.04µMPoint of departure: one standard deviation difference in viable cell count from control mean. 2-Ethylhexyl diphenyl phosphate28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean4.725763568287641µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 2-Ethylhexyl diphenyl phosphate28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean0.952046720545135µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. 2-Ethylhexyl diphenyl phosphate28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean1.00313766803373µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. 2,2’,4,4’-Tetrabromodiphenyl ether28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean16.43µMPoint of departure: one standard deviation difference in viable cell count from control mean. 2,2’,4,4’-Tetrabromodiphenyl ether28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean37.47275749468281µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 2,2’,4,4’-Tetrabromodiphenyl ether28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean4.379233356637162µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. 2,2’,4,4’-Tetrabromodiphenyl ether28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean0.820807195506619µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. 3,3',5,5'-tetrabromobisphenol A28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean21.99µMPoint of departure: one standard deviation difference in viable cell count from control mean. 3,3',5,5'-tetrabromobisphenol A28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean3.7178748024825206µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 3,3',5,5'-tetrabromobisphenol A28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean4.373443185166591µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. 3,3',5,5'-tetrabromobisphenol A28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean22.995461338703304µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. 3,3',5,5'-tetrabromobisphenol A33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF052.311.624.6942TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 5-Fluorouracil28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean>30µMPoint of departure: one standard deviation difference in viable cell count from control mean. 5-Fluorouracil28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean>100µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 5-Fluorouracil28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean>100µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. 5-Fluorouracil28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean>30µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. 5-Fluorouracil33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF052.941.2152.742TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 5-Fluorouracil21328588Mandenius, 2011in vitroHL-1RespirationEC500.360.250.5µM 5-Fluorouracil25034007Eskandari, 2014in vitroARVMsCell viability2hIC5015.0µM 5-Fluorouracil24704391Lamberti, 2014in vitroH9c2Cell viability72hIC50400.0µM 5-Fluorouracil25671635Focaccetti, 2015in vitroHCMsCell viability72hIC504.866µM 5-Fluorouracil35101590Li, 2022in vitroH9c2Cell viability48hIC505.0µM Aconitine30410440Ma, 2018in vitroH9c2Cell viability24hIC5032.0µM Aconitine31975431Li, 2020in vivoZebrafishMortality48hLD507.926.499.83µM Aconitine31975431Li, 2020in vitroH9c2Cell viability30mIC504.4113.685.59mM Aconitine18779382Wang, 2008in vitroH9c2Kv2.1IC501.4µM Aconitine24052561Guo, 2013in vitrohiPSC-CMsArrhythmiaIB200.03µMLowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. Aconitine24052561Guo, 2013in vitrohiPSC-CMsBeat rateBR20(↑) 0.01 µMLowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. Amitriptyline25237062Scott, 2014in vitrohiPSC-CMsPeak amplitudeIC506.65µMDecrease in amplitude Amitriptyline25237062Scott, 2014in vitrohiPSC-CMsBeat rateIC506.78µMDecrease in beat rate Amitriptyline25538221Pointon, 2015in vitrohiPSC-CMsCa2+ peak countIC500.4881095666666670.220.7µMPeak count: number of contractions over a period of time. Amitriptyline25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient widthIC500.6305555121926370.260.99µMWidth of the calcium transient Amitriptyline25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient amplitudeIC500.4899359666666670.240.68µMPeak amplitude of the calcium peak as measurement for contractility Amitriptyline25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient rise timeIC500.76504580011607850.450.95µM Amitriptyline25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient decay timeIC500.52653463413886030.310.75µM Amitriptyline25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient spacingIC500.365934444533269070.160.56µM Amitriptyline28069985Pointon, 2017in vitro3D cardiac microtissue (hiPSC-CMs, hCMECs, hCFs)Peak countIC504.99715602664461.018569383524945µMPeak count: number of contractions over a period of time. Amitriptyline33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF052.92.143.9742TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. Amitriptyline27130441Stoetzer, 2016in vitroNRVMsNav1.5IC5013.012.014µM Amitriptyline29239964Tsujikawa, 2018in vitroGuinea pig CMsSodium currentIC500.39µM Amitriptyline24052561Guo, 2013in vitrohiPSC-CMsArrhythmiaIB20> 30 µMLowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. Amitriptyline24052561Guo, 2013in vitrohiPSC-CMsBeat rateBR203.0µMLowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. Amsacrine1958848Dorr, 1991in vitroNRCMsCell viability3-6hIC5030.0µg/(ml h) Anthracene28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean9.13µMPoint of departure: one standard deviation difference in viable cell count from control mean. Anthracene28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean>100µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Anthracene28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean>100µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Anthracene28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean18.41468005066611µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Anthracene33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF052.311.1612.342TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. Arsenic trioxide24052561Guo, 2013in vitrohiPSC-CMsArrhythmiaIB203.0µMLowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. Arsenic trioxide24052561Guo, 2013in vitrohiPSC-CMsBeat rateBR201.0µMLowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. Benz(a)anthracene28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean10.78µMPoint of departure: one standard deviation difference in viable cell count from control mean. Benz(a)anthracene28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean>100µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Benz(a)anthracene28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean61.0621878095161µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Benz(a)anthracene28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean0.348807682728123µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Benz(a)anthracene33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF052.571.213.242TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. Benzo(a)pyrene28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean1.43µMPoint of departure: one standard deviation difference in viable cell count from control mean. Benzo(a)pyrene28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean>100µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Benzo(a)pyrene28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean42.98451393910572µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Benzo(a)pyrene28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean2.30172365931584µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Benzo(e)pyrene28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean8.32µMPoint of departure: one standard deviation difference in viable cell count from control mean. Benzo(e)pyrene28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean>100µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Benzo(e)pyrene28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean56.156909284493615µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Benzo(e)pyrene28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean6.957456397836642µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Benzo(e)pyrene33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF052.441.1811.842TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. Benzo(e)pyrene33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF052.771.21842TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. Berberine chloride28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean6.24µMPoint of departure: one standard deviation difference in viable cell count from control mean. Berberine chloride28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean0.59768133641112µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Berberine chloride28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean0.07024175002302288µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Berberine chloride28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean0.01146528847415449µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Berberine chloride29233041Zhang, 2018in vitroNRCMsPeak amplitude1.5hIC502.1µM Berberine chloride16424781Menchaca, 2006in vitroHEK-293hERGIC503.1µM Bisphenol A28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean>30µMPoint of departure: one standard deviation difference in viable cell count from control mean. Bisphenol A28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean27.303798623491115µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Bisphenol A28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean3.8649802059351606µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Bisphenol A28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean>30µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Bisphenol A33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF0513.75.2851.242TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. Bisphenol A34419494Hyun, 2021in vitrohiPSC-CMsCa2+ currentIC506.95.8000000000000018µM Bisphenol A34419494Hyun, 2021in vitrohiPSC-CMsNa+ currentIC5056.538.674.4µM Bortezomib23315586Pointon, 2013in vitrohESC-CMsATPIC500.0050.0040.005µMATP as measurement for mitochondrial dysfunction Bortezomib23315586Pointon, 2013in vitrohESC-CMsΔΨmIC500.0060.0050.006µMΔΨm: mitochondrial membrane potential Bortezomib23315586Pointon, 2013in vitrohESC-CMsCa2+ mobilizationIC500.060.0590.06µMInhibition of Ca2+ mobilization compared to control Bortezomib23315586Pointon, 2013in vitrohESC-CMsER integrityIC5086.986.3287.47µMMeasured with ER Tracker (imaging) Bortezomib28546047Koci, 2017in vitrohiPSC-CMsBeat rate20% change0.3µM Bortezomib28546047Koci, 2017in vitrohiPSC-CMsCell viability72h20% decrease1.0µM Cadmium (Cd2+)34255886Haverinen, 2021in vitroRainbow trout CMsCa2+ currentIC500.98µML-type Ca2+ current (ICaL) Cadmium (Cd2+)34255886Haverinen, 2021in vitroRainbow trout CMsNa+ currentIC50261.3188.10000000000002334.5µM Carbachol11750078Howard, 2002in vitroRat cardiac membraneMuscarinic receptor bindingIC507.04.012nMAdult rat cardiac membrane Carbachol11750078Howard, 2002in vitroRat cardiac membraneMuscarinic receptor bindingIC5020.09.044nMNeonatal rat cardiac membrane Chlorpyrifos28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean>30µMPoint of departure: one standard deviation difference in viable cell count from control mean. Chlorpyrifos28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean47.62225939818692µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Chlorpyrifos28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean12.384918691990402µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Chlorpyrifos28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean22.57527340474811µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Chlorpyrifos33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF057.043.3723.742TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. Chlorpyrifos11750078Howard, 2002in vitroRat cardiac membraneMuscarinic receptor bindingIC507.0nMAdult rat cardiac membrane Chlorpyrifos11750078Howard, 2002in vitroRat cardiac membraneMuscarinic receptor bindingIC5015.0nMNeonatal rat cardiac membrane Chlorpyrifos-methyl19674799Tryfonos, 2009in vitroSparus aurataContractility30mIC5093.789.797.9µM Cocaine16406254Ma, 2006in vitroGuinea pig CMsSodium currentIC5045.9µM15 μM suppressed AP upstroke velocity from ∼22 mV/ms to less than 5 mV/ms Cresyl diphenyl phosphate (CDP)25661707Du, 2015in vivoZebrafishPericardium effusion96hEC501.12µM Daunorubicin1958848Dorr, 1991in vitroNRCMsCell viability3-6hIC5016.5µg/(ml h) Daunorubicin21328588Mandenius, 2011in vitroHL-1RespirationEC500.120.120.14µMOxygen uptake rates, or respiration, provide direct information on the metabolic activity in cells and therefore on cellular homeostasis. Daunorubicin33719006Bozza, 2021in vitrohiPSC-CMsCell viability48hIC500.33µM Daunorubicin21046361Vavrova, 2011in vitroH9c2Cell viability24hIC500.48µM Daunorubicin17587482Adamcova, 2007in vitroNRVMsCell viability72hIC500.55µM Daunorubicin31650569Gwarda, 2019in vitroH9c2Cell viability24hIC500.64µM Di(2-ethylhexyl)phthalate 28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean>30µMPoint of departure: one standard deviation difference in viable cell count from control mean. Di(2-ethylhexyl)phthalate 28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean>100µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Di(2-ethylhexyl)phthalate 28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean12.218047963208406µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Di(2-ethylhexyl)phthalate 28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean5.883878124999231µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Di(2-ethylhexyl)phthalate 33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF051000.01.5345700042TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. Diazinon19674799Tryfonos, 2009in vivoSparus aurataContractility30mIC50164.0458.0170µM Dibenz(a,c)anthracene28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean>30µMPoint of departure: one standard deviation difference in viable cell count from control mean. Dibenz(a,c)anthracene28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean>100µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Dibenz(a,c)anthracene28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean>100µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Dibenz(a,c)anthracene28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean11.9864929394371µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Dibenz(a,c)anthracene33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF058.562.7247.642TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. Dieldrin28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean0.76µMPoint of departure: one standard deviation difference in viable cell count from control mean. Dieldrin28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean0.21827059281214095µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Dieldrin28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean1.07628932709562µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Dieldrin28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean0.47321013894299896µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Dieldrin33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF052.381.1712.742TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. Doxorubicin23315586Pointon, 2013in vitrohESC-CMsATPIC500.0030.0020.003µMATP as measurement for mitochondrial dysfunction Doxorubicin23315586Pointon, 2013in vitrohESC-CMsΔΨmIC5010.610.5210.67µMΔΨm: mitochondrial membrane potential Doxorubicin23315586Pointon, 2013in vitrohESC-CMsCa2+ mobilizationIC5040.7840.541.05µMInhibition of Ca2+ mobilization compared to control Doxorubicin23315586Pointon, 2013in vitrohESC-CMsER integrityIC50>100µMMeasured with ER Tracker (imaging) Doxorubicin25237062Scott, 2014in vitrohiPSC-CMsPeak amplitudeIC504.75µMDecrease in amplitude Doxorubicin25237062Scott, 2014in vitrohiPSC-CMsBeat rateIC504.75µMDecrease in beat rate Doxorubicin25538221Pointon, 2015in vitrohiPSC-CMsCa2+ peak countIC50>100µMPeak count: number of contractions over a period of time. Doxorubicin25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient widthIC5040.7667059859915538.0642.07µMWidth of the calcium transient Doxorubicin25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient amplitudeIC50>100µMPeak amplitude of the calcium peak as measurement for contractility Doxorubicin25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient rise timeIC503.63206126388640142.145.12µM Doxorubicin25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient decay timeIC5013.8855428413872243.3823.45µM Doxorubicin25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient spacingIC50>100µM Doxorubicin28069985Pointon, 2017in vitro3D cardiac microtissue (hiPSC-CMs, hCMECs, hCFs)Peak countIC5047.6988211020229043.37782831788947µMPeak count: number of contractions over a period of time. Doxorubicin35488128Gryshovka, 2022in vitrohiPSC-CMsCell viability24hIC503.0µM Doxorubicin1958848Dorr, 1991in vitroNRCMsCell viability3-6hIC505.72 µg/(ml h) Doxorubicin28546047Koci, 2017in vitrohiPSC-CMsBeat rate20% change3.0µM Doxorubicin28546047Koci, 2017in vitrohiPSC-CMsCell viability72h20% decrease3.0µM Doxorubicin21328588Mandenius, 2011in vitroHL-1RespirationEC500.430.380.5µM Doxorubicin33719006Bozza, 2021in vitrohiPSC-CMsCell viability48hIC500.54µM Doxorubicin28300219Zhao, 2017in vitrohiPSC-CMsCell viability48hIC503.5µM Doxorubicin31650569Gwarda, 2019in vitroH9c2Cell viability24hIC500.65µM Doxorubicin34525346Magdy, 2021in vitrohiPSC-CMsCell viability72hIC502.622µM Doxorubicin34525346Magdy, 2021in vitrohiPSC-CMsCaspase 3/7 activity24hEC502.078µM Doxorubicin34525346Magdy, 2021in vitrohiPSC-CMsROS72hEC5010.35µM Doxorubicin31797733Weng, 2020in vitroOrgan on chip incl. hiPSC-CMsBeat rate48hIC500.04107µMNormalized rate change (%), R2 = 0.79. Doxorubicin31797733Weng, 2020in vitroOrgan on chip incl. hiPSC-CMsBeat rate48hIC500.2298µMNormalized Max. rate change (%), R2 = 0.82. Doxorubicin32185414Karhu, 2020in vitrohiPSC-CMsCell viability48hIC500.8µMR2 = 0.83. Doxorubicin32185414Karhu, 2020in vitroNRVMsCell viability48hIC500.48µMR2 = 0.98. Doxorubicin24704391Lamberti, 2014in vitroH9c2Cell viability72hIC500.12µM Doxorubicin15273722Kluza, 2004in vitroH9c2Cell viability24hIC500.90.890.91µM Doxorubicin24052561Guo, 2013in vitrohiPSC-CMsArrhythmiaIB201.0µMLowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. Doxorubicin24052561Guo, 2013in vitrohiPSC-CMsBeat rateBR2010.0µMLowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. Endosulfan33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF053.812.37.2242TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 5-Fluorouracil23315586Pointon, 2013in vitrohESC-CMsATPIC5093.092.3893.61µMATP as measurement for mitochondrial dysfunction 5-Fluorouracil23315586Pointon, 2013in vitrohESC-CMsΔΨmIC500.090.0890.09µMΔΨm: mitochondrial membrane potential 5-Fluorouracil23315586Pointon, 2013in vitrohESC-CMsCa2+ mobilizationIC500.030.0370.038µMInhibition of Ca2+ mobilization compared to control 5-Fluorouracil23315586Pointon, 2013in vitrohESC-CMsER integrityIC500.060.050.06µMMeasured with ER Tracker (imaging) 5-Fluorouracil24052561Guo, 2013in vitrohiPSC-CMsArrhythmiaIB20> 30 µMLowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. 5-Fluorouracil24052561Guo, 2013in vitrohiPSC-CMsBeat rateBR20> 30 µMLowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. Idarubicin23315586Pointon, 2013in vitrohESC-CMsATPIC500.130.120.13µMATP as measurement for mitochondrial dysfunction Idarubicin23315586Pointon, 2013in vitrohESC-CMsΔΨmIC500.0130.0120.013µMΔΨm: mitochondrial membrane potential Idarubicin23315586Pointon, 2013in vitrohESC-CMsCa2+ mobilizationIC500.01340.01330.0134µMInhibition of Ca2+ mobilization compared to control Idarubicin23315586Pointon, 2013in vitrohESC-CMsER integrityIC500.0020.0010.002µMMeasured with ER Tracker (imaging) Idarubicin1958848Dorr, 1991in vitroNRCMsCell viability3-6hIC500.84µg/(ml h) Idarubicin33719006Bozza, 2021in vitrohiPSC-CMsCell viability48hIC500.25µM Idarubicin34787021Zhang, 2021in vitrohl-1Cell viability24hIC507.0µM Idarubicin24052561Guo, 2013in vitrohiPSC-CMsArrhythmiaIB200.3µMLowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. Idarubicin24052561Guo, 2013in vitrohiPSC-CMsBeat rateBR203.0µMLowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. Imatinib23315586Pointon, 2013in vitrohESC-CMsATPIC5015.715.5915.8µMATP as measurement for mitochondrial dysfunction Imatinib23315586Pointon, 2013in vitrohESC-CMsΔΨmIC5026.025.8226.17µMΔΨm: mitochondrial membrane potential Imatinib23315586Pointon, 2013in vitrohESC-CMsCa2+ mobilizationIC5020.420.2620.53µMInhibition of Ca2+ mobilization compared to control Imatinib23315586Pointon, 2013in vitrohESC-CMsER integrityIC5052.051.6552.34µMMeasured with ER Tracker (imaging) Imatinib35488128Gryshovka, 2022in vitrohiPSC-CMsCell viability24hIC2030.0µM Imatinib28315715Chambers, 2017in vitroH9c2Cell viability24hIC5026.219.133.3µM Imatinib30910525Burke, 2019in vitroRat CFsCell viability24hIC5014.8µM Imatinib30910525Burke, 2019in vitroRat CFsCell viability48hIC5011.0µM Imatinib22641616Hu, 2012in vitroNRCMsATP24hLOAEL12.5µMLowest dose that caused significant change from the vehicle control Imatinib22641616Hu, 2012in vitroNRCMsLDH24hLOAEL25.0µM Imatinib22641616Hu, 2012in vitroNRCMsCaspase 3/7 activity24hLOAEL12.5µM Imatinib22641616Hu, 2012in vitroNRCMsΔΨm24hLOAEL25.0µM Imatinib22641616Hu, 2012in vitroNRCMsXBP1 splicing24hLOAEL10.0µM Imatinib22641616Hu, 2012in vitroNRCMsCHOP induction24hLOAEL10.0µM Imatinib18664550Will, 2008in vitroH9c2ATP24hIC5030.5329.0731.99µMGlucose containing media Imatinib18664550Will, 2008in vitroH9c2ATP24hIC5029.1727.430.94µMGalactose containing media Imatinib18664550Will, 2008in vitroH9c2Complex 1 activity24hIC50>300µM Imatinib18664550Will, 2008in vitroH9c2Complex 5 activity24hIC50190.0µM Imatinib35216404Bouitbir, 2022in vitroH9c2ATP24hIC5019.5µMGlucose containing media Imatinib35216404Bouitbir, 2022in vitroH9c2ATP24hIC5022.3µMGalactose containing media Imatinib24052561Guo, 2013in vitrohiPSC-CMsArrhythmiaIB2030.0µMLowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. Imatinib24052561Guo, 2013in vitrohiPSC-CMsBeat rateBR2010.0µMLowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. Lead chloride28836190Mattos, 2017in vivoGuinea pig heartContractilityIC5055.0µMAmplitude of contraction (tension in gf/cm2) Lead chloride28836190Mattos, 2017in vitroGuinea pig CMsCa2+ currentIC5018.010.026µMCav1.2 channel (ICa) Lindane28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean>30µMPoint of departure: one standard deviation difference in viable cell count from control mean. Lindane28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean12.142755544523702µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Lindane28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean3.6574232703683207µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Lindane28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean14.524658940031504µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Lindane33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF055.721.89438042TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. Loperamide27530870Kang, 2016in vitroHEK-293Nav1.5IC50297.0nMHolding potential of -90 mV Loperamide27530870Kang, 2016in vitroHEK-293Nav1.5IC50239.0nMHolding potential of -70 mV Loperamide27530870Kang, 2016in vitroHEK-293hERGIC5089.0nMRoom temperature Loperamide27530870Kang, 2016in vitroHEK-293hERGIC5033.0nMPhysiological temperature Mitomycin A1458553Dorr, 1992in vitroNRCMsCell viability3hIC502.1µM Mitomycin C1458553Dorr, 1992in vitroNRCMsCell viability3hIC50>274µM Mitoxantrone23315586Pointon, 2013in vitrohESC-CMsATPIC500.40.390.4µMATP as measurement for mitochondrial dysfunction Mitoxantrone23315586Pointon, 2013in vitrohESC-CMsΔΨmIC503.23.173.22µMΔΨm: mitochondrial membrane potential Mitoxantrone23315586Pointon, 2013in vitrohESC-CMsCa2+ mobilizationIC503.33.273.32µMInhibition of Ca2+ mobilization compared to control Mitoxantrone23315586Pointon, 2013in vitrohESC-CMsER integrityIC503.43.373.42µMMeasured with ER Tracker (imaging) Mitoxantrone1958848Dorr, 1991in vitroNRCMsCell viability3-6hIC504.0µg/(ml h) Mitoxantrone28546047Koci, 2017in vitrohiPSC-CMsBeat rate20% change1.0µM Mitoxantrone28546047Koci, 2017in vitrohiPSC-CMsCell viability72h20% decrease1.0µM Mitoxantrone23261645Schweikart, 2013in vitrohiPSC-CMsCell viability1hIC50127.0µM Mitoxantrone23261645Schweikart, 2013in vitrohiPSC-CMsCell viability12hIC503.1µM Mitoxantrone23261645Schweikart, 2013in vitrohiPSC-CMsCell viability72hIC500.5µM Mitoxantrone23261645Schweikart, 2013in vitrohiPSC-CMsATP72hIC500.8µM Mitoxantrone15273722Kluza, 2004in vitroH9c2Cell viability24hIC501.61.31.9µM Mitoxantrone24052561Guo, 2013in vitrohiPSC-CMsArrhythmiaIB203.0µMLowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. Mitoxantrone24052561Guo, 2013in vitrohiPSC-CMsBeat rateBR200.3µMLowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. Nifedipine22972846Sirenko, 2013in vitrohiPSC-CMsBeat rateIC500.12µM Nifedipine23315586Pointon, 2013in vitrohESC-CMsATPIC50>100µMATP as measurement for mitochondrial dysfunction Nifedipine23315586Pointon, 2013in vitrohESC-CMsΔΨmIC50>100µMΔΨm: mitochondrial membrane potential Nifedipine23315586Pointon, 2013in vitrohESC-CMsCa2+ mobilizationIC50>100µMInhibition of Ca2+ mobilization compared to control Nifedipine23315586Pointon, 2013in vitrohESC-CMsER integrityIC50>100µMMeasured with ER Tracker (imaging) Nifedipine25219538Gibson, 2014in vitrohiPSC-CMsCa2+ currentIC500.039µMAfter acute exposure Nifedipine25237062Scott, 2014in vitrohiPSC-CMsPeak amplitudeIC507.37µMDecrease in amplitude Nifedipine25237062Scott, 2014in vitrohiPSC-CMsBeat rateIC502.2742in % of control because plateau was not reached, EC50 could not be calculated Nifedipine25538221Pointon, 2015in vitrohiPSC-CMsCa2+ currentIC500.93µMCalcium channel inhibitor Nifedipine25538221Pointon, 2015in vitrohiPSC-CMsCa2+ peak countIC500.9330965666666670.381.72µMPeak count: number of contractions over a period of time. Nifedipine25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient widthIC501.28868512771158520.861.7µMWidth of the calcium transient Nifedipine25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient amplitudeIC500.3611448333333330.240.46µMPeak amplitude of the calcium peak as measurement for contractility Nifedipine25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient rise timeIC500.65512966114602570.40.8µM Nifedipine25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient decay timeIC501.41637376171070730.116.14µM Nifedipine25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient spacingIC500.25424882996478620.030.84µM Nifedipine28069985Pointon, 2017in vitro3D cardiac microtissue (hiPSC-CMs, hCMECs, hCFs)Peak countIC500.0341194463263489940.005484630147128975µMPeak count: number of contractions over a period of time. Nifedipine31385592Feric, 2019in vitro3D cardiac microtissue (hiPSC-CMs, cardiac fibroblasts)ContractilityIC5062.0nMChange in contractile force Nifedipine33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF0520.88.767.442TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. Nifedipine33813278Lee, 2021in vitrohiPSC-CMsPeak amplitudeIC500.3µMParameter of contractile force. Nifedipine21328588Mandenius, 2011in vitroHL-1RespirationEC50>1000µM Nifedipine24052561Guo, 2013in vitrohiPSC-CMsArrhythmiaIB20> 3 µMLowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. Nifedipine24052561Guo, 2013in vitrohiPSC-CMsBeat rateBR20(↑) 0.1 µMLowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. Paraoxon19674799Tryfonos, 2009in vivoSparus aurataContractility30mIC503.23.173.32µM Parathion28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean15.09µMPoint of departure: one standard deviation difference in viable cell count from control mean. Parathion28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean7.462307505897089µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Parathion28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean3.58245730566495µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Parathion28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean12.321953100837701µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Parathion-methyl19674799Tryfonos, 2009in vivoSparus aurataContractility30mIC5080.375.1685.7µM Permethrin28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean>30µMPoint of departure: one standard deviation difference in viable cell count from control mean. Permethrin28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean>100µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Permethrin28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean0.07997352002027538µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Permethrin28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean0.337715562209982µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Permethrin33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF052.491.2112.642TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. Phenanthrene28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean>30µMPoint of departure: one standard deviation difference in viable cell count from control mean. Phenanthrene28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean33.29727119738452µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Phenanthrene28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean8.049186382259762µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Phenanthrene28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean22.17945338031911µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Phenanthrene33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF0537.54.0883642TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. Phenanthrene33906022Abramochkin, 2021in vitroNavaga cod CMsK+ currentIC501.951.852.05µMAtrial Ikr potassium current Phenanthrene33906022Abramochkin, 2021in vitroNavaga cod CMsK+ currentIC502.21.92.5µMVentricular Ikr potassium current Pyrene28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean>30µMPoint of departure: one standard deviation difference in viable cell count from control mean. Pyrene28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean>100µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Pyrene28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean2.1992719630538µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Pyrene28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean4.0062179400930304µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Pyrene33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF052.361.1712.342TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. Rosiglitazone24052561Guo, 2013in vitrohiPSC-CMsArrhythmiaIB20> 30 µMLowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. Rosiglitazone24052561Guo, 2013in vitrohiPSC-CMsBeat rateBR20(↑)1 µMLowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. Rosiglitazone24249632Mishra, 2014in vitroH9c2Cell viability24hIC5055.050.060µM Rosiglitazone21774756Szebeni, 2011in vitroCanine VCMsItoIC5025.222.527.9µMIto: Cardiac transient outward potassium current Rosiglitazone21774756Szebeni, 2011in vitroCanine VCMsIkrIC5072.363.081.6µMIkr: Rapid delayed rectifier potassium current Rosiglitazone21774756Szebeni, 2011in vitroCanine VCMsCa2+ currentIC5082.573.191.9µM Sibutramine18781376Kim, 2009in vitroHEK-293hERGIC502.5µMAt -40 mV Sibutramine18829731Kim, 2008in vitroCHO cellshERGIC502.411.92.9µg/mL Sibutramine18829731Kim, 2008in vitroARVMsNa+ currentIC507.725.989.46µg/mL Sibutramine18829731Kim, 2008in vitroARVMsCa2+ currentIC502.792.323.26µg/mL Tebuconazole28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean>30µMPoint of departure: one standard deviation difference in viable cell count from control mean. Tebuconazole28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean34.886491754886805µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Tebuconazole28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean7.820019423184851µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Tebuconazole28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean10.027007638969604µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Tebuconazole32798748Othmene, 2020in vitroH9c2Cell viability24hIC5050.0µM Tebuconazole35202779Miranda, 2022in vitroMouse VCMsCa2+ currentIC5033.225.80000000000000440.6µML-type calcium channel inhibitor Tebuconazole35202779Miranda, 2022in vitroMouse VCMsK+ currentIC505.74.27.2µMIK potassium current inhibition Telmisartan23073892Kim, 2012in vitroRat isolated heartInfarction sizeEC5048.1µM Telmisartan18664324Tu, 2008in vitroOocyteshKv1.5IC502.251.283.22µMPeak current Telmisartan18664324Tu, 2008in vitroOocyteshERGIC5024.3519.2929.41µM Telmisartan18664324Tu, 2008in vitroOocyteshKv1.5IC500.820.431.21µM1.5 second end-pulse current Tributyl phosphate (TBP)25661707Du, 2015in vivoZebrafishPericardium effusion96hEC5066.5µM Triethyl phosphate (TEP)25661707Du, 2015in vivoZebrafishPericardium effusion96hEC506820.0µM Triphenyl phosphate (TPhP)28259702Sirenko, 2017in vitrohiPSC-CMsCell viability24h1 SD from control mean10.05µMPoint of departure: one standard deviation difference in viable cell count from control mean. Triphenyl phosphate (TPhP)28259702Sirenko, 2017in vitrohiPSC-CMsMitochondrial dysfunction30m1 SD from control mean0.682448714400104µMPoint of departure: one standard deviation difference in granule intensity (JC-10) from control mean. Triphenyl phosphate (TPhP)28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)30m1 SD from control mean1.9162149312627903µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Triphenyl phosphate (TPhP)28259702Sirenko, 2017in vitrohiPSC-CMsPeak frequency (beats per minute)24h1 SD from control mean18.377242139483506µMPoint of departure: one standard deviation difference in peak frequency (BPM) from control mean. Triphenyl phosphate (TPhP)25661707Du, 2015in vivoZebrafishPericardium effusion96hEC501.97µM Tripropyl phosphate (TPrP)25661707Du, 2015in vivoZebrafishPericardium effusion96hEC50933.0µM Tris-(1,3-dichloro-2-propyl) phosphate (TDCPP)25661707Du, 2015in vivoZebrafishPericardium effusion96hEC503.83µM Tris-(2-butoxyethyl) phosphate (TBEP)25661707Du, 2015in vivoZebrafishPericardium effusion96hEC5010.3µM Tris-(2-chloroethyl) phosphate (TCEP)25661707Du, 2015in vivoZebrafishPericardium effusion96hEC50626.0µM Tris-(2-chloropropyl) phosphate (TCPP)25661707Du, 2015in vivoZebrafishPericardium effusion96hEC5069.5µM Verapamil22972846Sirenko, 2013in vitrohiPSC-CMsBeat rateIC500.055µM Verapamil25237062Scott, 2014in vitrohiPSC-CMsPeak amplitudeIC507.25µMDecrease in amplitude Verapamil25237062Scott, 2014in vitrohiPSC-CMsBeat rateIC507.44µM Verapamil25538221Pointon, 2015in vitrohiPSC-CMsCa2+ currentIC500.32µML-type calcium channel inhibitor Verapamil25538221Pointon, 2015in vitrohiPSC-CMsCa2+ peak countIC500.3157623266666670.10.64µMPeak count: number of contractions over a period of time. Verapamil25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient widthIC500.077540590178875380.010.13µMWidth of the calcium transient Verapamil25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient amplitudeIC500.02122897333333330.010.03µMPeak amplitude of the calcium peak as measurement for contractility Verapamil25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient rise timeIC500.139000176432245880.010.2µM Verapamil25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient decay timeIC500.03496764437286530.020.04µM Verapamil25538221Pointon, 2015in vitrohiPSC-CMsCa2+ transient spacingIC500.0191151758305446660.010.03µM Verapamil26983082Gossmann, 2016in vitrohiPSC-CMsPeak amplitudeIC50150.0µMPeak amplitude of the contraction peak. Verapamil28069985Pointon, 2017in vitro3D cardiac microtissue (hiPSC-CMs, hCMECs, hCFs)Peak amplitudeIC505.162.0213.1µMPeak amplitude of the contraction peak. Verapamil28069985Pointon, 2017in vitro3D cardiac microtissue (hiPSC-CMs, hCMECs, hCFs)Peak countIC500.16903759877467570.1588335009827040742µMPeak count: number of contractions over a period of time. Verapamil33078833Blanchette, 2020in vitrohiPSC-CMsCell viability90 minTDVF055.872.1926.642TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. Verapamil21328588Mandenius, 2011in vitroHL-1RespirationEC5032.031.036µM Verapamil24585781Stoehr, 2014in vitroCardiac construct, hiPSCContractilityIC50968.1nM Verapamil24052561Guo, 2013in vitrohiPSC-CMsArrhythmiaIB20> 30 µMLowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. Verapamil24052561Guo, 2013in vitrohiPSC-CMsBeat rateBR20(↑) 0.03 µMLowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control.